Suppression of specific PRAM activation/populations represents a potential therapeutic strategy for the treatment of ROP and other ocular disorders associated with microglia-driven RNV (e.g., PDR) or CNV (e.g., age-related macular degeneration). Here, PRAM1 is linked to age-related macular degeneration.